Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Befiradol (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Proof of concept
- Sponsors Neurolixis
- 15 Jan 2024 According to a Neurolixis media release, results of this study were discussed in a new interview between Arthur Roach, director of Parkinson's UK Virtual Biotech, and Adrian Newman-Tancredi, CEO of Neurolixis.
- 27 Jun 2023 According to a Neurolixis media release, this study was supported by Parkinson's UK (grant DYS-20-02) and The Michael J. Fox Foundation (grant MJFF- 019508).
- 27 Jun 2023 According to a Neurolixis media release, detailed results from this trial will be presented at the forthcoming World Parkinson's Congress (WPC) 2023.